In the notice with the above heading, published in the New Zealand Gazette, 3 June 2020, Notice No. 2020-go2377. This corrigendum amends the notice by replacing the entry:
Schedule
Product: | Necon 0.5/35 |
Active Ingredients: | Ethinylestradiol 0.035mg Norethisterone 0.5mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | Link Pharmaceuticals Limited |
Manufacturer: | Teva Women’s Health Inc, Ohio, United States of America |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for six months from the date of publication of this notice. |
With:
Product: | Necon 0.5/35 |
Active Ingredients: | Ethinylestradiol 0.035mg Norethisterone 0.5mg |
Dosage Form: | Tablet |
Dosage Form: | Placebo Tablet |
New Zealand Sponsor: | Link Pharmaceuticals Limited |
Manufacturer: | Teva Women’s Health Inc, Ohio, United States of America |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for six months from the date of publication of this notice. |
Dated this 15th day of June 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).